肠道宏基因组特征可预测非酒精性脂肪性肝病相关肝硬化的肝功能失代偿与死亡
在一项前瞻性队列中,对25例非酒精性脂肪性肝病(NAFLD)相关肝硬化成人粪便行鸟枪法宏基因组测序,用随机森林算法识别出13个物种组成的失代偿特征,诊断准确度0.97(95%CI 0.96-0.99),外部验证AUC 0.95(95%CI 0.81-1.00),该特征预测死亡风险强于终末期肝病模型评分。
要点
- 13个物种的粪便宏基因组特征诊断NAFLD相关肝硬化失代偿的准确度为0.97(95%CI 0.96-0.99)。
- 该特征在独立验证队列中AUC为0.95(95%CI 0.81-1.00)。
- 该特征预测全因死亡的HR为1.54(95%CI 1.10-2.15,p=0.01),强于终末期肝病模型评分的HR 1.25(95%CI 1.03-1.53,p=0.03)。
核心结论
- 该研究为肠道宏基因组衍生特征提供了证据,该特征对NAFLD相关肝硬化的肝功能失代偿具有高诊断准确度,并可预测死亡风险。
研究设计与样本
- 前瞻性队列研究,纳入25例NAFLD相关肝硬化成人,研究 entry 时采集粪便行鸟枪法宏基因组测序,用随机森林机器学习算法识别失代偿肝硬化特征,并在外部队列验证。
- 失代偿肝硬化定义为腹水、肝性脑病或食管胃底静脉曲张出血。
- 采用Cox比例风险回归模型分析全因死亡的预测因素。
主要发现
- 在16例失代偿肝硬化参与者中,33%有腹水,56%有肝性脑病,22%曾发生食管胃底静脉曲张出血(非互斥)。
- 识别出由13个具鉴别力的物种组成的粪便宏基因组特征,区分失代偿NAFLD相关肝硬化的诊断准确度为0.97(95%CI 0.96-0.99)。
- 校正乳果糖使用后,13物种特征的诊断准确度AUC为0.99;校正利福昔明使用后AUC为0.93。
- 13物种宏基因组特征在独立测试队列中AUC为0.95(95%CI 0.81-1.00)。
- 13物种宏基因组特征预测死亡的HR为1.54(95%CI 1.10-2.15,p=0.01),终末期肝病模型评分的HR为1.25(95%CI 1.03-1.53,p=0.03)。
关键数值与推荐
- 13物种粪便宏基因组特征诊断失代偿NAFLD相关肝硬化的准确度为0.97(95%CI 0.96-0.99)。
- 校正乳果糖后AUC为0.99,校正利福昔明后AUC为0.93。
- 独立验证队列中AUC为0.95(95%CI 0.81-1.00)。
- 13物种特征预测死亡的HR为1.54(95%CI 1.10-2.15,p=0.01),终末期肝病模型评分HR为1.25(95%CI 1.03-1.53,p=0.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data on the diagnostic accuracy of gut microbial signatures for predicting hepatic decompensation in patients with cirrhosis. AIMS: To determine whether a stool metagenome-derived signature accurately detects hepatic decompensation and mortality risk in cirrhosis secondary to non-alcoholic fatty liver disease (NAFLD) METHODS: Shotgun metagenomic sequencing was performed on faecal samples collected at study entry from a prospective cohort of adults with NAFLD-related cirrhosis. A Random Forest machine learning algorithm was utilised to identify a metagenomic signature of decompensated cirrhosis (defined by ascites, hepatic encephalopathy or variceal haemorrhage) and subsequently validated in an external cohort. A Cox proportional hazards regression model was used to examine predictors of all-cause mortality. RESULTS: In all, 25 adults with NAFLD-related cirrhosis (training cohort) were included. Among the 16 participants with decompensated cirrhosis, 33% had ascites, 56% had hepatic encephalopathy and 22% had experienced a variceal haemorrhage (not mutually exclusive). We identified a stool metagenomic signature comprising 13 discriminatory species that reliably distinguished decompensated NAFLD-related cirrhosis (diagnostic accuracy, 0.97, 95% confidence interval [CI] 0.96-0.99). Diagnostic accuracy of the 13-species signature remained high after adjustment for lactulose (area under the curve [AUC] 0.99) and rifaximin use (AUC 0.93). The discriminative ability of 13-species metagenomic signature was robust in an independent test cohort (AUC 0.95, 95% CI 0.81-1.00). The 13-species metagenomic signature (hazard ratio [HR] 1.54, 95% CI 1.10-2.15, p = 0.01) was a stronger predictor of mortality than the Model for End-Stage Liver Disease score (HR 1.25, 95% CI 1.03-1.53, p = 0.03). CONCLUSIONS: This study provides evidence for a gut metagenome-derived signature with high diagnostic accuracy for hepatic decompensation that predicts risk of mortality in NAFLD-related cirrhosis.
引用
- Sharpton SR, Oh TG, Madamba E, et al. Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis. Aliment Pharmacol Ther. 2022. PMID: 36164267. doi:10.1111/apt.17236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。